Background: Psoriasis is systemic, immune-mediated skin disease. Recent advances in pathogenesis have led to the importance of microRNAs [miRNAs] detected in sera of patients which were found to be up-regulated or down-regulated and showed correlations with PASI score. Thus, miRNAs could serve as promising biomarkers for diagnosis, progression and significant target for the treatment of psoriasis.
Aim of the work: This study aimed to evaluate the role of miRNA-106b, miRNA-223, and miRNA-125a in psoriasis and to investigate the relationship between their expression and the severity of disease.
Patients and methods: This prospective case control study was carried out on 30 psoriatic patients and 20 age and gender matched volunteers. The severity of the disease was graded by PASI score. miRNA-106b, miRNA-223, and miRNA-125a were analyzed by PCR.
Results: Expression of miRNA-106b and miRNA-125a were statistically significant up-regulated in the studied patients [p=0.001 and p=0.037, respectively], and expression of miRNA-223 was statistically significant down-regulated in the studied patients [p=0.003].
Conclusion: MicroRNA-106b and miRNA-125a were up-regulated and miRNA-223 was down-regulated in psoriatic patients. Those results support the role of miRNAs in the pathogenesis of psoriasis and could open the gate for their use as biomarkers for early diagnosis, prognosis and as new emerging targeted treatments of psoriasis in future.